Does FDA's Category B classification automatically produce Medicare payment for the device?

No, this is a frequent and costly misconception: Category B classification by FDA is a necessary but not sufficient condition, and sites or sponsors must still separately pursue and obtain CMS coverage approval and demonstrate the study meets routine-cost coverage criteria under 42 CFR 405.201 through 405.215 before Medicare will actually pay. Sponsors who assume classification equals payment often discover the gap only after enrollment has begun.

When should sponsors coordinate the CMS coverage submission relative to the FDA IDE submission?

Sponsors should initiate the CMS coverage approval process in parallel with, or shortly after, the FDA IDE submission rather than waiting until FDA approval is finalized, since sequential rather than parallel engagement is a common cause of avoidable trial-funding delays. Early coordination allows study budget and site contracting to reflect the actual expected payer mix for both routine costs and, where applicable, the device itself.

How does IDE coverage classification affect overall trial economics?

A Category B device with approved CMS coverage effectively converts device costs from sponsor-borne to third-party-payer-reimbursed for enrolled Medicare beneficiaries, which can substantially change per-patient trial cost assumptions and site willingness to enroll Medicare-eligible patients. This makes IDE coverage classification a meaningful input to trial budgeting and site selection strategy, not merely a regulatory formality.

All terms

ReimbursementClinical Evidence Global Markets Hospital Buyer & Reimbursement

CMS IDE Coverage (Category A & B)

Medicare coverage framework for items and services furnished in FDA-approved IDE studies, Category A (experimental) and Category B (non-experimental).

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

Under 42 CFR 405 Subpart B, CMS may cover routine costs and, for Category B IDEs, the device itself when furnished in an FDA-approved investigational device exemption study. FDA classifies an IDE device as Category A (experimental, novel risk-benefit profile not yet established) or Category B (non-experimental, generally a follow-on or substantial-equivalent design). Category B devices may be covered by Medicare; Category A devices generally are not, though routine costs may still be covered under the Clinical Trial Policy NCD 310.1.

What the regulation says

42 CFR 405.201-405.215 (IDE coverage), NCD 310.1 (Clinical Trial Policy), and the joint FDA-CMS process for IDE classification at study approval.

What this means in practice

IDE coverage decisions can dramatically alter trial economics, a Category B classification with CMS coverage approval converts trial-device costs from sponsor-borne to payer-reimbursed.

Examples

A sponsor developing a new diagnostic imaging system for a rare neurological condition receives FDA approval for an IDE study. Since the device is considered highly experimental with an unestablished risk-benefit profile, FDA designates it as Category A, meaning Medicare will likely only cover the routine costs associated with the clinical trial, not the device itself.
A company is testing an incremental improvement to an already approved surgical implant that has a well-understood safety profile. The FDA designates this IDE as Category B, potentially allowing Medicare to cover both the routine costs of the trial and the cost of the investigational device for eligible beneficiaries.
During an IDE study for a novel drug-eluting stent, the device is classified as Category B by the FDA due to its similarity to existing technologies. This classification significantly impacts the trial's budget, as participating hospitals can bill Medicare for the device's cost, reducing the financial burden on the device manufacturer.

Common pitfalls

•Assuming Category B classification automatically yields Medicare coverage, sites must still seek CMS approval and meet routine-cost criteria.
•Failing to coordinate FDA IDE submission with the CMS coverage submission early.

Frequently asked questions

FDA designates an investigational device as Category A when its underlying risk-benefit profile has not yet been established (a genuinely novel or experimental device), or Category B when it is a non-experimental, generally follow-on device whose type has an established risk-benefit profile; under 42 CFR 405 Subpart B, Category B devices may be covered by Medicare while Category A devices generally are not. Routine care costs surrounding the study, aside from the device itself, may still be covered for either category under the Clinical Trial Policy NCD 310.1 if study and coverage criteria are met.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Reimbursement

LCD and NCD

Local and National Coverage Determinations from Medicare.

Reimbursement

National and Local Coverage Determinations(NCD / LCD)

Medicare coverage policies issued nationally (NCD) or by individual MAC contractors (LCD).

Clinical & Trials

IDE Supplement

Amendment to an approved Investigational Device Exemption for protocol or device changes.

Clinical & Trials

Investigational Device Exemption(IDE)

FDA authorization to use an investigational device in a clinical study.

More in Reimbursement

· Same category

Reimbursement

340B Drug Pricing Program(340B)

Federal program providing discounted drugs to safety-net providers.

Reimbursement

Ambulatory Payment Classification(APC)

The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient.

Reimbursement

ASC Site-of-Service Shift

Migration of procedures from hospitals to ambulatory surgery centers.

Reimbursement

Budget Impact Model(BIM)

Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (3)

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Official citation replacements checked: 2026-11-01. Medicare documents support Medicare coding, coverage or payment context, not every payer policy or CPT editorial procedure. Citation replacement does not change the full term review date.

Tier 1Binding law and standards· 3Tier 2Regulator guidance and consensus· 1

Link health: 2 verified 2 unchecked· last checked 2026-06-20

CMS·1eCFR·3

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Reimbursement0 / 37

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Reimbursement
Sources: 4
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Medicare coverage framework for items and services furnished in FDA-approved IDE studies, Category A (experimental) and Category B (non-experimental).

·IDE coverage decisions can dramatically alter trial economics, a Category B classification with CMS coverage approval converts trial-device costs from sponsor-borne to payer-reimbursed.
·FDA classifies an IDE device as Category A (experimental, novel risk-benefit profile not yet established) or Category B (non-experimental, generally a follow-on or substantial-equivalent design).
·Category B devices may be covered by Medicare; Category A devices generally are not, though routine costs may still be covered under the Clinical Trial Policy NCD 310.1.

Remember this

Watch out: Assuming Category B classification automatically yields Medicare coverage, sites must still seek CMS approval and meet routine-cost criteria.

Related terms

You may also need

Auto-suggested from Reimbursement and shared keywords.

All Reimbursement terms